References
- Kuttan G, Kuttan R. Immunologicalinvestigations 1992; 21222: 285–296
- Kuttan G. Immunological Investigations 1993; 22: 431–440
- Franz H. Pharmazie 1985; 40: 97–104
- Franz H. Oncology 1986; 43: 23–34
- Jordan E, Wagner H. Oncology 1986; 43: 8–15
- Antony S, Kuttan R, Kuttan G. Immunological investigations 1999; 28: 1–8
- Vitalo D, Vujanovic N, Rabinovich H, Schlesinger M, Herberman R B, Whiteside T L. J.Immunol 1993; 151: 926–1937
- Fresa Kerin L., Murasko Donna M. Cancer Res 1986; 46: 81–88
- Bergman I, Loxley R. Clin. Chim Acta 1970; 27: 347–349
- Skoza L, Mohos S. Biochem J 1976; 159: 457–462
- Tate S S, Meister A. Biol Chem 1974; 23: 7593–7602
- Beuth J, Steur M K, Lenartz D, Pulverer G. Z Alleg Med 1996; 72: 24–27
- Matthiessen V F, Troger V. In combinerte tumour therapie, H. Wrba. Hippocrates verlag., Stuttgart 1990; 271–290
- Hajto T, Hostanska K, Friek K, Rordorf C, Gabius H J. Cancer Res 1990; 50: 3322–3326
- Bloom E T, Takasugy M. NK cells and other natural effector cells, R.B. Herberman, 1982; pp. 675–680
- Herberman R B, Brunda M J, Cannon G B, Djeu J Y, Nunn M E, Hargrove, Jett J R, Ortaldo J R, Reynolds C, Riccardi C, Santoni A. Augmenting agents in cancer therapy, E.M. Hersh, et al, 1981; 253
- Domzig W, Stadler B M. NK cells and other natural effector cells, R.B. Herberman., 1982; 409–414
- Yogeswaran G. Adv Cancer Res; 1983; 38: 289–350
- Passaniti A, Hart G V. J. Biol. Chem 1988; 263: 7591–7603
- Rentae R, Lion E., Hunter R. Lab Invest 1981; 44: 44–48